Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Amylyx Pharmaceuticals, Inc. (AMLX)

25.275   -0.975 (-3.71%) 06-09 13:19
Open: 26.21 Pre. Close: 26.25
High: 26.34 Low: 25.24
Volume: 183,463 Market Cap: 1,698(M)

Technical analysis

as of: 2023-06-09 12:43:17 PM
Short-term rate:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Mid-term rate:       
Target: Six months: 32.5     One year: 35.62
Support: Support1: 23.5    Support2: 19.55
Resistance: Resistance1: 27.82    Resistance2: 30.5
Pivot: 25.74
Moving Average: MA(5): 25.72     MA(20): 26.19
MA(100): 31.34     MA(250): 30.24
MACD: MACD(12,26): -0.9     Signal(9): -1
Stochastic oscillator: %K(14,3): 53.7     %D(3): 50.7
RSI: RSI(14): 41.3
52-week: High: 41.93  Low: 12.71
Average Vol(K): 3-Month: 953 (K)  10-Days: 1,086 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ AMLX ] has closed above bottom band by 41.9%. Bollinger Bands are 27.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 26.3 - 26.37 26.37 - 26.46
Low: 25.2 - 25.29 25.29 - 25.4
Close: 26.08 - 26.23 26.23 - 26.39

Company Description

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Headline News

Fri, 09 Jun 2023
Oversea Chinese Banking CORP Ltd Invests $620000 in Amylyx ... - MarketBeat

Thu, 08 Jun 2023
Amylyx Pharmaceuticals Inc. (AMLX) vs. S&P500: A Comparative ... - The Dwinnex

Wed, 07 Jun 2023
Acquisition of Stake in Amylyx Pharmaceuticals Inc. by Raymond ... - Best Stocks

Tue, 06 Jun 2023
Amylyx Pharmaceuticals to Pres -

Tue, 06 Jun 2023
Amylyx Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference - Yahoo Finance

Wed, 31 May 2023
HC Wainwright & Co. Reiterates Amylyx Pharmaceuticals (AMLX ... - Nasdaq

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 67 (M)
Shares Float 40 (M)
% Held by Insiders 23.4 (%)
% Held by Institutions 81.9 (%)
Shares Short 8,530 (K)
Shares Short P.Month 6,100 (K)

Stock Financials

EPS -2.49
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 5.26
Profit Margin (%) -159.1
Operating Margin (%) -166.2
Return on Assets (ttm) -28.5
Return on Equity (ttm) -50.2
Qtrly Rev. Growth 0
Gross Profit (p.s.) -1.11
Sales Per Share 1.39
EBITDA (p.s.) -2.31
Qtrly Earnings Growth 0
Operating Cash Flow -144 (M)
Levered Free Cash Flow -84 (M)

Stock Valuations

PE Ratio -10.26
PEG Ratio 0.5
Price to Book value 4.83
Price to Sales 18.23
Price to Cash Flow -11.84

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.